Literature DB >> 17706308

Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer.

Cesare Cozzarini1, Claudio Fiorino, Nadia Di Muzio, Filippo Alongi, Sara Broggi, Mauro Cattaneo, Francesco Montorsi, Patrizio Rigatti, Riccardo Calandrino, Ferruccio Fazio.   

Abstract

PURPOSE: To assess and quantify the possible benefit deriving from IMRT with Helical Tomotherapy (HTT) delivery to the pelvic nodal area in patients with prostate cancer in terms of reduction of acute and late toxicities. METHODS AND MATERIALS: Thirty-five patients candidate to radical or postoperative RT on whole pelvis (WPRT) were treated with HTT, while receiving a concomitant boost to the prostate or the prostatic bed (median 74.2 and 72 Gy, respectively) within a moderately hypofractionated (28-33 fractions; median HTT duration 44 days) regimen. Median and mean doses to whole pelvis were 52 and 54 Gy, respectively. One of the major goals of planning optimisation was to minimize the dose received by the intestinal cavity (IC) outside the nodal PTV.
RESULTS: HTT resulted to be very efficient in sparing the IC even at dose levels below 30-35 Gy and guaranteed a significant sparing of bladder and rectum even at intermediate-low doses (V20-V40). No acute Grade 3 RTOG toxicity was recorded. Eighteen G1 and two G2 GU acute toxicities, 13 G1 upper GI acute toxicities, 8 G1 and 1 G2 acute proctitis were observed; no patient experienced G2 upper GI toxicity. After a median FU of 11.5 months (>10 in 18 patients) one case of late G3 GU toxicity was reported in one post-prostatectomy treated patient; no G2 late rectal bleeding or other GI toxicity was recorded.
CONCLUSIONS: WPRT with HTT resulted in a very low incidence of acute Grade 2 and in the disappearance of acute Grade 3 toxicities.

Entities:  

Mesh:

Year:  2007        PMID: 17706308     DOI: 10.1016/j.radonc.2007.07.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

1.  Reduction of dosimetric impact of intrafractional prostate motion during helical tomotherapy.

Authors:  V Prokic; H Geinitz; P Kneschaurek
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

2.  Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales.

Authors:  Giuseppe Ferrera; Gianluca Mortellaro; Mariella Mannino; Giovanni Caminiti; Antonio Spera; Vanessa Figlia; Giuseppina Iacoviello; Gioacchino Di Paola; Rosario Mazzola; Antonio Lo Casto; Filippo Alongi; Maria Pia Pappalardo; Roberto Lagalla
Journal:  Radiol Med       Date:  2015-05-24       Impact factor: 3.469

3.  Dosimetric and volumetric effects in clinical target volume and organs at risk during postprostatectomy radiotherapy.

Authors:  Ahmed Gawish; Ahmed Ali Chughtai; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2018-10-17       Impact factor: 3.621

4.  Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.

Authors:  Hua-chun Luo; Li-ping Cheng; Hui-hua Cheng; Zhi-chao Fu; Shao-guang Liao; Dong-shi Li; Wen-fa Zheng; Gui-shan Lin; Jin-feng Zhu; Jian-feng Xu; Qin Yin; Qing-yang Yu
Journal:  Med Oncol       Date:  2014-05-22       Impact factor: 3.064

5.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

6.  Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms.

Authors:  R A Schneider; V Vitolo; F Albertini; T Koch; C Ares; A Lomax; G Goitein; E B Hug
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

7.  The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.

Authors:  F Alongi; B De Bari; P Franco; P Ciammella; T Chekrine; L Livi; B A Jereczek-Fossa; A R Filippi
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

8.  A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.

Authors:  Johanne Hermesse; Sylvie Biver; Nicolas Jansen; Eric Lenaerts; Nathalie De Patoul; Stefaan Vynckier; Philippe Coucke; Pierre Scalliet; Philippe Nickers
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

9.  (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.

Authors:  M Picchio; G Berardi; A Fodor; E Busnardo; C Crivellaro; G Giovacchini; C Fiorino; M Kirienko; E Incerti; C Messa; L Gianolli; N Di Muzio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-06       Impact factor: 9.236

Review 10.  The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Giorgio Gandaglia; Cesare Cozzarini; Alexandre Mottrie; Alberto Bossi; Nicola Fossati; Francesco Montorsi; Alberto Briganti
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.